Osteoporosis remains a major cause of morbidity and mortality. Parathyroid hormone (PTH) is the only currently available therapy that substantially increases bone mass, but this therapy's effectiveness wanes with time. Our lack of understanding of the limitations of PTH therapy reflects very incomplete understanding of why PTH increases bone mass. We need to understand better the cellular targets of PTH and the intracellular mediators of PTH action. We propose to clarify both the cellular targets of PTH action and to identify a previously missed link in the action of PTH on osteocytes.
In Aim 1, we propose to characterize early cells of the osteoblast lineage in vivo. These cells are likely PTH targets (direct and indirect), but our ability to identify these cells and study how PTH changes them in vivo is limited. We will mark such early cells in the osteoblast lineage with a collagen 11-creERt transgene that will activate expression of a red fluorescent marker (tandem dimer tomato). We will determine the fates of such cells (how they differentiate into osteoblasts and adipocytes, how they proliferate and die, whether they participate in fracture repair). We will define their gene expression and will study how PTH changes their fates and activities in ways that may clarify the anabolic action of PTH and its limitations. We will also study bone lining cells to identify how PTH activates these cells to become active osteoblasts.
In Aim 2, we will study the roles of class IIa histone deacetylases (HDACs) in mediating PTH's action to suppress expression of sclerostin, a powerful inhibitor of wnt signaling secreted by osteocytes. We have shown that these HDACs mediate PTHrP's action in chondrocytes and hypothesize that, as in chondrocytes, HDACs respond to PTH by moving to the nucleus and suppressing transcription by Mef2 transcription factors. We will test this hypothesis using an osteocyte cell line from Dr. Divieti Pajevic and using knockout mice. We view sclerostin regulation as a model for many actions of PTH on all cells of the osteoblast lineage. Thus, by defining early cells of the lineage and a novel mediator of PTH signaling, we hope to clarify the mechanisms that can lead to more effective therapies.

Public Health Relevance

Parathyroid hormone (PTH) is a powerful but limited therapy for osteoporosis. Our goal is to define early cells of the lineage of bone-forming cells that mediate actions of PTH and to define a signaling pathway key to the actions of PTH. With this work we hope to provide tools needed to develop more effective osteoporosis therapies.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Grigelioniene, Giedre; Nevalainen, Pasi I; Reyes, Monica et al. (2017) A Large Inversion Involving GNAS Exon A/B and All Exons Encoding Gs? Is Associated With Autosomal Dominant Pseudohypoparathyroidism Type Ib (PHP1B). J Bone Miner Res 32:776-783
Roszko, Kelly L; Bi, Ruiye; Gorvin, Caroline M et al. (2017) Knockin mouse with mutant G?11 mimics human inherited hypocalcemia and is rescued by pharmacologic inhibitors. JCI Insight 2:e91079
Mitchell, Deborah M; J├╝ppner, Harald; Burnett-Bowie, Sherri-Ann M (2017) FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls. J Clin Endocrinol Metab 102:1151-1160
Li, Yuwen; Caballero, Daniel; Ponsetto, Julian et al. (2017) Response of Npt2a knockout mice to dietary calcium and phosphorus. PLoS One 12:e0176232
Leaf, David E; Jacob, Kirolos A; Srivastava, Anand et al. (2017) Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness. J Am Soc Nephrol 28:1877-1885
Knab, Vanessa M; Corbin, Braden; Andrukhova, Olena et al. (2017) Acute Parathyroid Hormone Injection Increases C-Terminal but Not Intact Fibroblast Growth Factor 23 Levels. Endocrinology 158:1130-1139
Guo, Jun; Khatri, Ashok; Maeda, Akira et al. (2017) Prolonged Pharmacokinetic and Pharmacodynamic Actions of a Pegylated Parathyroid Hormone (1-34) Peptide Fragment. J Bone Miner Res 32:86-98
Balani, Deepak H; Ono, Noriaki; Kronenberg, Henry M (2017) Parathyroid hormone regulates fates of murine osteoblast precursors in vivo. J Clin Invest 127:3327-3338
Kim, Sang Wan; Lu, Yanhui; Williams, Elizabeth A et al. (2017) Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts. J Bone Miner Res 32:892-901
Ono, Noriaki; Kronenberg, Henry M (2016) Bone repair and stem cells. Curr Opin Genet Dev 40:103-107

Showing the most recent 10 out of 208 publications